1110 — Kingworld Medicines Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Kingworld Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	745	847	958	1,079	1,061
Cost of Revenue
Gross Profit	280	264	278	281	270
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	672	775	885	982	971
Operating Profit	73.6	72.2	72.2	96.8	89.7
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	70.9	69.4	67.6	93.9	95.5
Provision for Income Taxes
Net Income After Taxes	50.9	51.2	43.5	61.6	74.5
Minority Interest
Net Income Before Extraordinary Items
Net Income	11.7	30.3	22.7	38.1	41.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	11.7	30.3	22.7	38.1	41.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.018	0.052	0.037	0.065	0.074
Dividends per Share